. However, it is not known whether renal afferent nerves are influenced by sympathetic nerve activity. We tested the hypothesis that norepinephrine (NE) influences voltage-gated Ca 2ϩ channel currents in cultured renal dorsal root ganglion (DRG) neurons, i.e., the first-order neuron of the renal afferent pathway. DRG neurons (T11-L2) retrogradely labeled from the kidney and subsequently cultured, were investigated by whole-cell patch clamp. Voltage-gated calcium channels (VGCC) were investigated by voltage ramps (Ϫ100 to ϩ80 mV, 300 ms, every 20 s). NE and appropriate adrenergic receptor antagonists were administered by microperfusion. NE (20 M) reduced VGCC-mediated currents by 10.4 Ϯ 3.0% (P Ͻ 0.01). This reduction was abolished by the ␣-adrenoreceptor inhibitor phentolamine and the ␣ 2-adrenoceptor antagonist yohimbine. The ␤-adrenoreceptor antagonist propranolol and the ␣ 1-adrenoceptor antagonist prazosin had no effect. The inhibitory effect of NE was abolished when N-type currents were blocked by -conotoxin GVIA, but was unaffected by other specific Ca 2ϩ channel inhibitors (-agatoxin IVA; nimodipine). Confocal microscopy revealed sympathetic innervation of DRGs and confirmed colocalization of afferent and efferent fibers within in the kidney. Hence NE released from intrarenal sympathetic nerve endings, or sympathetic fibers within the DRGs, or even circulating catecholamines, may influence the activity of peptidergic afferent nerve fibers through N-type Ca 2ϩ channels via an ␣2-adrenoceptordependent mechanism. However, the exact site and the functional role of this interaction remains to be elucidated. dorsal root ganglion; renal afferent neuron; ␣ 2-adrenoreceptor; voltage-gated Ca 2ϩ channel; VGCC; -agatoxin RENAL NERVES PLAY AN IMPORTANT role in physiological and pathological conditions, as shown by numerous renal denervation experiments. Recently, renal denervation was used successfully to treat drug-resistant hypertension in humans (16, 30) . However, the role of renal afferent nerves and their putative interaction with renal efferent nerves are not well understood. The kidney is innervated by efferent sympathetic and afferent peptidergic nerve fibers (13). The importance of afferent renal nerves was first uncovered with the discovery of renorenal reflexes. Increasing renal pelvic pressure stimulated ipsilateral afferent renal nerves and downregulated contralateral renal efferent sympathetic-mediated effects (11, 28). Furthermore, renal afferent denervation delays development of hypertension in some models of secondary hypertension and reduces the extent of the blood pressure rise (7, 8, 40, 55) . However, renal afferent denervation has also been shown to result in salt-sensitive hypertension in otherwise healthy rats (29). These observations suggest an important role of renal afferent nerves in the generation and control of blood pressure and sympathetic tone. Afferent renal nerves contain neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P (SP), which are released during inflammation and likely in environments with increased proton concentrations (49). Both CGRP and SP are vasodilators that can also act as proinflammatory mediators (5). Hence renal afferents not only transmit information from the periphery to the central nervous system but they also have a local "efferent" function that subserves inflammatory processes (14, 50) .
RENAL NERVES PLAY AN IMPORTANT role in physiological and pathological conditions, as shown by numerous renal denervation experiments. Recently, renal denervation was used successfully to treat drug-resistant hypertension in humans (16, 30) . However, the role of renal afferent nerves and their putative interaction with renal efferent nerves are not well understood. The kidney is innervated by efferent sympathetic and afferent peptidergic nerve fibers (13) . The importance of afferent renal nerves was first uncovered with the discovery of renorenal reflexes. Increasing renal pelvic pressure stimulated ipsilateral afferent renal nerves and downregulated contralateral renal efferent sympathetic-mediated effects (11, 28) . Furthermore, renal afferent denervation delays development of hypertension in some models of secondary hypertension and reduces the extent of the blood pressure rise (7, 8, 40, 55) . However, renal afferent denervation has also been shown to result in salt-sensitive hypertension in otherwise healthy rats (29) . These observations suggest an important role of renal afferent nerves in the generation and control of blood pressure and sympathetic tone.
Afferent renal nerves contain neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P (SP), which are released during inflammation and likely in environments with increased proton concentrations (49) . Both CGRP and SP are vasodilators that can also act as proinflammatory mediators (5) . Hence renal afferents not only transmit information from the periphery to the central nervous system but they also have a local "efferent" function that subserves inflammatory processes (14, 50) .
Given their putative role in tempering central sympathetic outflow and their influence on inflammatory responses in the kidney, it seems likely that afferent nerves are influenced by the sympathetic nervous system. Sympathetic renal nerve activity might regulate afferent renal nerves by intrarenally released norepinephrine (NE). Furthermore, there is evidence in the literature that dorsal root ganglia themselves might contain sympathetic fibers (18) . The underlying mechanism of the putative interaction between renal efferent sympathetic nerves and peptidergic afferents is as yet unknown. However, voltagegated Ca 2ϩ channels (VGCCs) are regulated by NE in neurons (4, 17) . VGCCs regulate intracellular calcium levels and activation of action potentials of excitable cells such as neurons or muscle cells (39) .
The influence of sympathetic nerves on afferent renal nerve fibers within the kidney or the dorsal root ganglia (DRG) is not easily addressable using conventional in vivo or in vitro experimental set-ups. We developed a cell culture model for DRG neurons that allows us to investigate renal afferent neurons (12, 33) . Studying the cell bodies in culture could also serve as a model of afferent endings, since it has been shown that neuronal cell bodies share similar receptor expression patterns with their dendritic projections (21) .
We tested the hypothesis that NE influences VGCCs of renal afferents situated in DRGs. The effect of NE on DRG neurons in culture was studied with the whole-cell patch-clamp technique. Specific receptor antagonists and calcium channel blockers were used to elucidate the adrenoreceptor and VGCC subtypes involved in the observed responses. Additionally, we examined kidney slices and DRG tissue via confocal microscopy to demonstrate the juxtaposition of peptidergic afferents and sympathetic fibers (49) .
MATERIALS AND METHODS
Male Sprague-Dawley rats (Charles River, Kisslegg, Germany), weighing 250 -300 g, were maintained in cages at 24 Ϯ 2°C and fed a standard rat diet (no. C-1000, Altromin, Lage, Germany) containing 0.2% sodium by weight and were allowed free access to tap water.
All procedures performed in animals were done in accordance with the guidelines of the American Physiological Society and approved by the local government agency (Regierung von Mittelfranken, Ansbach, Germany).
Histological Investigation
Histological examination of kidney slices was performed to determine the relative proximity of renal efferent and afferent nerves (12, 49) , to confirm that an anatomic substrate exists for the postulated functional interaction. In addition, we examined DRGs to substantiate the putative existence of sympathetic nerves within the DRGs as an alternative site for the interaction of sympathetic nerves and sensory afferents.
For detection of sympathetic and sensory peptidergic nerve fibers, immunocytochemistry for tyrosine hydroxylase (TH) and CGRP was employed (3, 44, 51) . Briefly, 15-m cryostat sections from formaldehyde perfusion-fixed rat kidneys and T11-L2 DRGs were incubated with primary antibodies dissolved in TBS followed by incubation with appropriate fluorochrome-tagged secondary antibodies. Sections were examined with a Biorad MRC 1000 confocal system attached to a Nikon Diaphot 300 inverted microscope. The blue 488-nm and yellow 568-nm lines of a krypton-argon laser were used for excitation of Alexa 488 and Cy3, respectively, resulting in green and red fluorescence of the labeled nerve fibers. The blue 488-nm laser line was also used to elicit green autofluorescence in the kidney and thus used as a counterstain. Merged two-channel confocal images were adjusted for contrast and brightness using Adobe Photoshop CS5.
Labeling of DRG Neurons with Renal Afferents
Rats were anesthetized with isoflurane. Small bilateral flank incisions were made to expose the pole of each kidney. The retrograde neural tract tracer dicarbocyanine dye 1,1= dioleyl-3,3,3= tetramethylindocarbocyanine methansulfonate, ⌬9-DiI (DiI; 10 mg/ml in ethanol/ PBS, 70:30 vol/vol; Molecular Probes, Eugene, OR) was administered by subcapsular application (5 l). Care was taken to prevent backleak or spreading of DiI to surrounding tissue. Rats were given buprenorphine (0.05 mg/kg sc) for analgesia perioperatively and as necessary following surgery. One week later, the DRGs T11-L2 were excised as described previously and outlined briefly below (9, 34) .
Neuronal Cell Culture
Rats were deeply anesthetized with methohexital (25 mg/ml; 500 l ip) and euthanized by decapitation. DRGs from vertebral segments T11-L2 were exposed by laminectomy, quickly excised, and placed in ice-cold PBS. Primary DRG neurons were obtained by mechanical and enzymatic dissociation of tissue by methods adapted from previously described protocols (10) . The DRGs were incubated with collagenase IA (C9891, 2 mg/ml in DMEM; Sigma) for 1 h in 5% CO 2 at 37°C. Enzyme activity was terminated by removing collagenase containing DMEM and adding fresh DMEMϩ culture medium (ϩ10% FCS, 1% penicillin/streptomycin, and 0.1% insulin, Biochrom). Tissue digestion was stopped by FCS.
DRGs were triturated using sterile siliconized Pasteur pipettes (Sigmacote; Sigma) to dissociate individual cells. After centrifugation at 200 g, cells were resuspended in 10 ml DMEMϩ and centrifugation was repeated. The pellet was then resuspended in 1 ml DMEMϩ, and cells were plated on glass coverslips coated with poly-L-lysine, which were incubated for an additional 24 h before the electrophysiological experiments. Neurons were identified by the presence of fast sodium currents during repolarization.
Experimental Workflow
First, the effect of NE on VGCCs in DRG neurons from the kidney was established as the basic experimental protocol. Second, the adrenoreceptors involved in the NE effect were studied by use of different adrenoreceptor antagonists. Third, the VGCCs involved were identified by use of different Ca 2ϩ channel blockers.
Basic experimental setup: NE effects on VGCCs (patch-clamp technique)
. A whole-cell configuration (20, 33) was used to measure voltage-activated Ca 2ϩ currents. Coverslips containing cultures were transferred to a laminar flow chamber placed on an inverted phasecontrast microscope (Wilowert, Hund, Germany). The chamber was perfused with a standard bath solution (extracellular_0) containing (in mM) 140 NaCl, 5 KCl, 2 CaCl 2, 1 MgCl2, 10 HEPES, and 10 glucose, with pH adjusted to 7.4 with NaOH, at a flow rate of 0.5-1 ml/min by gravity-fed lines, connected to fluid reservoirs and a computer-controlled perfusion system (PF-8, E.S.F).
For the investigation of VGCCs, cultures were superfused with a 110 mM barium solution (extracellular_1) containing (in mM) 110 BaCl2, 5 CsCl, and 10 HEPES, adjusted to pH 7.45 with CsOH (19) . A multibarrel perfusion pipette was positioned 600 m from a target neuron while the superfusate was delivered from a reservoir with a pressure of 20 cmH2O. This method was chosen to keep the cultures in a physiological environment for the most part of the protocol to provide the most stable recording conditions possible in our setup.
The pipette solution (intracellular_A) contained (in mM) 120 CsCl, 3 MgCl2, 5 HEPES, 10 EGTA, and 2 Mg 2ϩ -ATP, with pH adjusted to 7.35 with CsOH.
Patch pipettes (resistance: 2-4 M⍀) were pulled from borosilicateglass capillaries (GB150F-8P; Science Products) in a two-stage process using a microelectrode puller and a microforge (PP-830, Narishige) to adjust the diameter of the pipette opening. Ca 2ϩ currents were recorded using an Axopatch 200B patch-clamp amplifier (Axon Instruments, Foster City, CA), controlled by a Digidata 1200 interface and pClamp 8.2 software (Axon Instruments). Signals were visualized by a digital oscilloscope (HM205-3, Hameg), traces were low-pass filtered at 2 kHz, digitized at 10 kHz, and stored on a computer hard drive for off-line analysis with pClamp 8.2.
Cell capacitance was obtained from current transients induced by 10-mV 66-Hz rectangular test pulses, using a software-based algorithm (pClamp 8.2) at a holding voltage of Ϫ80 mV. Series resistance was compensated electronically.
A laser beam (532 nm) mounted on the patch-clamp recording setup was used to detect DiI-labeled cells using appropriate optical filters. Only cells that were brightly labeled with DiI were classified as renal DRG neurons. In previous experiments, we found that the largest population of nonrenal DRG neurons in this preparation comes from the hindlimbs (33) . The basic experimental protocol was performed in labeled and unlabeled DRG neurons to compare renal and nonrenal afferents. All recordings were performed at room temperature (24°C).
Basic protocol: NE effect on VGCCs (voltage-clamp protocol). Voltage-activated Ca 2ϩ currents were evoked by 300-ms voltage ramps ranging from Ϫ100 to ϩ80 mV every 20 s, 15 times. Linear components of leak currents were subtracted digitally. Currents, read out as Ba 2ϩ -peak currents, were normalized to 1 at the control peak just before application of NE (20 M) during a 40-s interval starting just before the fourth voltage ramp. A typical linear VGCC rundown was observed. Cells with excessive or nonlinear rundown were excluded. Data were corrected for rundown subsequent to further analysis.
Identification of adrenoreceptors involved. The same basic protocol was used except that different adrenoreceptor antagonists were added to the NE solution and tested on separate groups of cells. Thus NE (20 M) was applied either together with phentolamine (20 M; nonse-
Identification of VGCCs involved. The type of VGCC involved was identified by use of different specific and nonspecific Ca 2ϩ channel blockers (31) . However, some of the inhibitors used did not work reliably in the experimental setup described for the basic protocol and the investigation of the adrenoreceptors (i.e., extracellular_1ϩ intracellular_A solution). Therefore, neurons were superfused with a 5 mM calcium-tetraethylammonium (TEA) solution (extracellular_2) containing (in M) 100 TEA-Cl (to inhibit K ϩ -conductances), 67 choline-Cl, 5 CsCl, 5 CaCl 2, and 10 HEPES. The pipette solution (extracellular_B) contained (in M) 140 CsCl, 3 MgCl 2, 10 HEPES, 10 EGTA, 5 Mg-ATP, 0.1 and Na-GTP, as adapted from protocols described by others (25, 31) . Otherwise, the experimental protocol was similar to that described above with the exception that up to 27 voltage ramps were used.
Confirmation of NE effect on VGCCs. The reproducibility of the NE effect was also tested under these conditions (extracellular_2ϩ intracellular_B solution). Again, 20 M NE was applied just before the fourth voltage ramp (40-s interval) and compared with the data acquired with the extracellular_1ϩintracellular_A solution.
Identification of VGCC type involved. After the NE effect was tested, we determined the effect of different Ca 2ϩ channel blockers in preliminary experiments to gain information on the baseline blocking characteristics of the drugs since some of the blockers were irreversible. Rundown correction was not done in this set of experiments to emphasize the baseline blocking properties, if present. Normalization to 1 was performed to provide comparability. The following blockers were used (25, 31): CdCl2 (10 and 100 M; nonselective Ca 2ϩ channel blocker); nimodipine and nifedipine (NIM and NIF, respectively; 10 M; L-type Ca 2ϩ channel blockers); mibefradil [MIB; 10 M; T/(L)-type Ca 2ϩ channel blocker]; the marine cone snail venom -conotoxin GVIA (CTX; 2 M; selective N-type Ca 2ϩ channel blocker); and the funnel web spider venom -agatoxin IVA (ATX; 1 M; P/Q-type Ca 2ϩ channel blocker). Blocking properties of the drugs were characterized, using a similar voltage-ramp protocol as above (Ϫ100 to ϩ80 mV every 20 s, 15-27 times; blockers applied between ramps 5 and 19). Subsequently, 20 M NE was applied together with the specific Ca 2ϩ -channel blockers (ATX, CTX, NIM) for a three-ramp-interval in the middle of the blocker administration period in a separate set of experiments.
All drugs and solutions were prepared as stock solutions and stored at Ϫ80°C and diluted to a final concentration on the day of the experiment. ATX and CTX were purchased from Bachem, and 0.1 mg/ml BSA (A-7906, Sigma) was added to stabilize the aqueous solution. All other Ca 2ϩ channel inhibitors and the adrenoreceptor antagonists were purchased from Sigma-Aldrich and prepared in aqueous/saline stock solutions.
Data Analysis
Cells with excessive or nonlinear rundown were excluded from analysis. Currents were normalized to 1 at the control peak just before drug application (voltage ramp 3) and corrected for rundown.
The effect of NE over the course of the experimental protocol was analyzed by one-way repeated measures ANOVA with Bonferroni comparison vs. control value, i.e., the voltage ramp 3 peak current. Subsequent experiments focused on renal neurons. The influence of the adrenoreceptor blockers on the NE effect, each tested in a separate group of renal DRG neurons, was similarly analyzed by one-way repeated measures ANOVA and Bonferroni pairwise comparison vs. control. Comparison of consecutive peak currents with and without blockers was done by using one-way ANOVA and Bonferroni pairwise comparison (NE vs. NEϩadrenoreceptor blocker). Data from Ca 2ϩ channel blocker experiments were analyzed similarly (35) . For statistical analysis, a commercially available software package (SigmaStat 2.0, Jandel Scientific) was used. Statistical significance was defined as P Ͻ 0.05 (2-sided). Data are presented as means Ϯ SE (46) . The nominal number of multiple comparisons (k) for the Bonferroni correction is given in the figure legends, where applicable.
RESULTS

DRG Neurons In Situ and In Culture
Labeled DRG neurons appeared as red-orange cells under epifluorescence. No difference in distribution of labeled (i.e., renal) and unlabeled (i.e., nonrenal) neurons was detected. Approximately 40% of neurons were positively labeled for DiI, indicating the cells contained afferent input from the kidneys. Between 15 and 20% of the cells of all cultures were very brightly labeled with DiI. These brightly labeled cells were defined as renal DRG neurons; clearly, unlabeled neurons were defined as nonrenal afferents.
Many, but not all cells showed positive CGRP labeling. A dense meshwork of TH-positive fibers was also found that appeared to contact afferent CGRP-positive neuron cell bodies (Fig. 1A) .
Renal nerve bundles containing TH-positive and CGRPpositive elements entered the kidney along the arteries. As previously shown (12, 49) , sympathetic axons traveled side by side within the same bundles, and all components of the cortex, i.e., glomeruli, tubuli, and blood vessels, were observed in close juxtaposition with afferent and efferent nerve fibers (Fig. 1B) .
Electrophysiological Data
A total of 290 cells were included in the statistical analysis. Baseline cellular parameters, including membrane resistance (R m ; M⍀), and membrane capacity (C m ; pF), both measured at Ϫ80-mV holding potential, reversal potential (P rev ; mV), and cell diameter (m; measured with an ocular mounted micrometer caliper), did not differ between renal or nonrenal cells or between experimental groups. Therefore, baseline data from all groups were pooled: mean R m was 291 Ϯ 16 M⍀; mean C m was 77.3 Ϯ 2.6 pF; mean P rev was Ϫ48.6 Ϯ 0.4 mV; and mean measured cell diameter was 33.4 Ϯ 0.4 m.
NE Effect on VGCCs
NE significantly reduced voltage-gated, whole-cell Ba 2ϩ currents used as a measure of VGCC-mediated Ca 2ϩ currents (25) by 10.4 Ϯ 3.0% (P Ͻ 0.01). Figure 2 illustrates the basic experimental protocol. NE reduced peak amplitude, but the activation voltage level was unaffected. Due to the typical rundown seen in VGCCs, the washout peak current did not completely recover to control levels. NE induced an approxi-mately 10% VGCC current reduction that could not be increased by higher doses of NE (50 M; data not shown). Figure 3 shows Ba 2ϩ peak currents plotted over time from DiI-positive and DiI-negative DRG neurons superfused with NE. Peak currents from labeled cells that were not exposed to NE are also shown with a linear regression line that represents an estimate of the naturally occurring rundown of VGCCs. Currents were significantly reduced by NE, but there was no difference between labeled or unlabeled cells. The following experiments focused on labeled DRG neurons.
Investigation of Adrenoreceptors Involved
Phentolamine completely abolished the inhibitory effect of NE, whereas propranolol had no significant effect. Yohimbine, but not prazosin also completely abolished the effect of NE (Figs. 4 and 5) .
Investigation of VGCCs
For technical reasons, in these experiments Ca 2ϩ instead of Ba 2ϩ served as the charge carrier. It was thus necessary to confirm the reproducibility of the inhibitory NE effect under these conditions. VGCC inhibition was similar; however, washout was significantly slower (Fig. 6) .
Characterization of VGCC Inhibition by Different Ca 2ϩ
Channel Blockers
Before testing the effect of different Ca 2ϩ channel blockers on the NE-induced VGCC inhibition, their effects alone were characterized. The nonselective Ca 2ϩ channel blocker CdCl 2 dose dependently inhibited Ca 2ϩ currents. The inhibitor could be completely washed out (Fig. 7) . The selective L-type Ca (Ϫ100 to ϩ80 mV; 300 ms) . NE was applied for 40 s after 3 control intervals (20 s each). Peak amplitude was reduced, but activation voltage remained unchanged. Due to VGCC rundown washout, amplitude was reduced compared with control condition. Fig. 3 . NE-induced VGCC inhibition, renal vs. nonrenal DRG neurons. Peak VGCC currents were normalized to 1 (control peak at 1 min, i.e., voltage ramp 3), and relative changes were plotted vs. time. NE (20 M) reversibly reduced peak currents. Controls without NE showed only the VGCC rundown. *P Ͻ 0.01, k ϭ 2, renal and nonrenal with NE vs. renal without NE.
blocker CTX (2 M) and selective P/Q-type Ca 2ϩ channel blocker ATX (1 M) showed strong blocking effects but could not be washed out, in the presence of divalent ions (32) . To approach the saturation dose of the Ca 2ϩ channel blockers used, substances were tested individually and sequentially. CTX (2 M) decreased the Ca 2ϩ currents by 58 Ϯ 4%, ATX (1 M), by 41 Ϯ 3%, measured at minute 3 after application, when tested individually.
When applied sequentially to achieve near-maximum VGCC inhibition, CTX (2 M) provided a near 60% Ca 2ϩ current inhibition and ATX reduced the currents an additional 18%. NIF had a minor, but nonsignificant effect on VGCC currents (Fig. 8) .
Effect of Selective Ca 2ϩ Channel Blockade on NE-Induced VGCC Inhibition
L-type channel blockers, did not significantly affect VGCC currents or the NE-induced VGCC inhibition. The selective P/Q-type Ca 2ϩ -channel blocker ATX (1 M) irreversibly blocked VGCC currents but did not affect the NE-induced VGCC inhibition. The selective N-type Ca 2ϩ -channel blocker CTX (2 M) similarly irreversibly blocked VGCC currents, but additionally completely abolished the NE-induced VGCC inhibition (Fig. 9) .
DISCUSSION
In the kidney, the close proximity of peptidergic afferent and sympathetic efferent nerve fibers suggests that interactions between these components may have a functional consequence. The findings of the present study support this view. In cultured renal peptidergic afferent neurons, NE was found to inhibit CTX-sensitive N-type VGCC (Cav2.2) via ␣ 2 -adrenoreceptors. Confocal imaging also revealed a dense meshwork of sympathetic nerve fibers in DRG. Furthermore, the close proximity of afferent and sympathetic efferent nerves previously described in the kidney was confirmed. Hence, our study demonstrates that renal afferent neurons express the molecular requirements to interact with the sympathetic neurotransmitter NE, and that the kidney and/or the DRG is a possible site of the sympatho-afferent interaction. Fig. 4 . Yohimbine-and NE-induced VGCC inhibition corrected for rundown. The specific ␣2-antagonist yohimbine (20 M) completely abolished the inhibitory effect of NE on VGCCs in renal DRG neurons. For determination of the relative NE-induced VGCC inhibition, rundown was eliminated by subtraction. NE-induced peak current reduction was 10.4 Ϯ 3%. *P Ͻ 0.01, NE vs. NEϩyohimbine. Fig. 5 . NE-induced VGCC inhibition and adrenoreceptor antagonists Relative Ba 2ϩ peak current reduction due to NE without and with different adrenoreceptor antagonists is displayed. Only the nonspecific ␣-antagonist phentolamine and the specific ␣2-antagonist yohimbine (20 M, each) influenced the inhibitory NE effect in renal DRG neurons. *P Ͻ 0.01, k ϭ 4, NE vs. NEϩadrenoreceptor antagonist. The NE-induced current reduction was similar under both conditions; however, washout was slower with Ca 2ϩ EC. Displayed are peak currents over time normalized to 1 and corrected for rundown. *P Ͻ 0.01, Ba 2ϩ EC vs. Ca 2ϩ EC. NE reduced overall VGCC current by ϳ10%. This inhibition was abolished by administration of the nonselective ␣-antagonist phentolamine and the ␣ 2 -antagonist yohimbine, but not by ␣ 1 -or ␤-antagonists. The NE-sensitive component of the Ca 2ϩ current was blocked by the N-type Ca 2ϩ channel blocker CTX. In contrast, the P/Q-type Ca 2ϩ -channel blocker ATX or the L-type Ca 2ϩ channel blockers NIM and NIF, as well as the T/(L)-type Ca 2ϩ -channel blocker MIB did not affect the NE-induced current inhibition.
Furthermore, the preliminary Ca 2ϩ channel blocker experiments provide insight into the functional expression of Ca 2ϩ channels on renal DRG neurons. When applied sequentially to achieve near-maximum VGCC inhibition, CTX provided ϳ60% Ca 2ϩ current inhibition, while ATX added another 18%. NIF added no further significant VGCC inhibition. When tested individually, CTX also showed a 60% reduction in current density, while ATX produced a 40% inhibition when applied alone. The L-or T/(L)-type blockers were ineffective when administered alone. The data indicate that N-and P/Qtype Ca 2ϩ channels mediate a major component of the of voltage-gated Ca 2ϩ conductance in cultured DRGs receiving renal afferent input, while L-and T-type channels play a minimal role.
Our study is the first to show that ␣ 2 -adrenoceptors influence N-type VGCCs in cultured renal afferent neurons. However, this is not a unique feature of these specialized cells, in contrast to other characteristics such as the recently described specialized frequency distribution of tonic and phasic response pattern to various stimuli in the population of renal DRG neurons (12) , which seems to be rather related to voltage-gated Na ϩ channels (54) than the mechanism described here.
A similar type of adrenoreceptor-VGCC coupling has been shown in rabbit vesical parasympathetic ganglia (1) . Furthermore, ␣ 2 -adrenoceptors have been described as functionally relevant binding sites on peptidergic afferent neurons in the skin (23, 24) . When we compared renal and nonrenal DRG cells, mainly with hindlimb projections (33) , no differences could be detected between the two subgroups with respect to calcium peak currents or NE-induced inhibition. Hence, the mechanism described here in the context of renal peptidergic afferent neurons may be conserved throughout the autonomous nervous system. Sympathetic nerves have been shown to inhibit intestinal motility via NE-dependent activation of inhibitory ␣ 2 -adrenoceptors expressed on myenteric neurons and their nerve endings (41, 47) . Various subtypes of Ca 2ϩ channels are involved in this ␣ 2 -adrenoceptor-mediated process: N-type Ca 2ϩ channel inhibition has been described in intestinal submucosal neurons (48) , and R-type Ca 2ϩ channel inhibition has been described in small intestinal myenteric neurons (4). The differential coupling of ␣ 2 -adrenoceptors to N-and R-type Ca 2ϩ -channels was related to differential expression of Ca 2ϩ channel subtypes in the different enteric plexi (4) .
In general, ␣ 2 -adrenoceptors inhibit calcium influx through voltage-gated Ca 2ϩ channels via inhibitory Go/Gi-proteindependent pathways in the nervous system (6, 15, 53) , either by inhibition of adenylate cyclase or by direct interaction with Ca 2ϩ channels (15) . Neurons of the autonomic nervous system express multiple Ca 2ϩ channel subtypes (45), including L-, N-, P/Q-, R-and T-type channels (4, 43) . N-type channels were found on DRG neurons (2) as well as on peptidergic afferent nerve fibers (26, 27) , and these voltage-gated Ca 2ϩ channels might even be involved in the regulation of somatosensory nociceptive nerve fiber endings, which share a lot of properties with visceral afferents.
Another study investigated the relationships between capsaicin sensitivity and the expression of voltage-dependent highthreshold (L-and N-type) and low-threshold (T-type) Ca 2ϩ -currents in cultured adult rat DRG neurons (42) . All neurons exhibited high-threshold Ca 2ϩ currents, but none of the capsaicin-sensitive cells expressed the low-threshold Ca 2ϩ channel type. Capsaicin and protons stimulate DRG cells by binding to TRPV1 receptors. We recently demonstrated that DRG cells with projections from the kidney express functionally relevant TRPV1 receptors (12) . Hence, our data confirm that peptidergic afferent nerves express N-type Ca 2ϩ -channels. channel blocker -conotoxin GVIA (CTX; 2 M), the P/Q-type Ca 2ϩ channel blocker -agatoxin IVA (ATX; 1 M), and the L-type Ca 2ϩ channel blocker nifedipine (NIF; 10 M) were applied sequentially. The bar width represents superfusion intervals of respective blockers, and bar height illustrates peak current before blockers were added. CTX and ATX showed additive effects, and NIF had no significant effect. *P Ͻ 0.01, baseline vs. CTX (at minute 3). **P Ͻ 0.01, CTX (at minute 3) vs. ATX (at minute 5). P ϭ not significant (ns), ATX (at minute 5) vs. NIF.
With respect to the kidney, there is as yet only limited evidence that voltage-gated Ca 2ϩ channel subtypes, including L-, T-, N-, and P/Q-type, are present within renal vascular and tubular tissue. Furthermore it is recognized that blockade of these Ca 2ϩ channels produces diverse actions on the renal microcirculation (22) . Neural N-type Ca 2ϩ channels have been identified on renal sympathetic nerves, but have not so far been observed on peptidergic afferent fibers from the kidney (22) .
The functional significance of altered renal peptidergic afferent nerve activity and/or secretory function by sympathetic drive remains to be determined.
Our morphological studies confirmed the proximity of sympathetic nerve fibers and peptidergic afferent innervation within the kidney (49) . These findings suggest, but do not necessarily prove, that an interaction of functional significance occurs between these two neural components within the kidney. NE release in the kidney likely occurs at specialized neuroeffector junctions, as suggested by ultrastructural studies (36, 37) . Specialized microdomains that are thought to play a role in neurotransmission were described on afferent and efferent arterioles, proximal tubules, and on renin-secreting granular epitheloid cells of the macula densa (36) .
Unfortunately, such ultrastructural evidence for renal afferent nerves is lacking (49) . Neither the precise functional role of afferent nerves nor the exact anatomic structures within the kidney that they contact have been clearly defined. An important question remains as to how close the association between efferent and afferent nerves must be for endogenously released NE to gain access to adrenergic receptors expressed on renal afferents.
Conclusions drawn from patch-clamp experiments performed in cultured neurons are based on the idea that the soma and the sensory fibers of primary afferent neurons share many properties and receptor expression patterns (21) . However, these neurons are highly polarized and are not readily accessible in the kidney. As such, it is not evident that the mechanisms described in our study play a significant role in the function of afferent fibers located in the kidney.
However, in our confocal imaging studies of in situ DRG neurons we found a dense meshwork of sympathetic fibers around the afferent neurons. This phenomenon, termed sympathetic sprouting, has been described in models of neuropathic pain after nerve injury (52) . Similar anatomic findings have been observed under normal conditions as well (18) . It should be emphasized, however, that the main focus of our study was to elucidate putative mechanisms of sympathoafferent interaction rather than the site of interaction. Nevertheless, the anatomic and ultrastructural relationship between sympathetic efferents and sensory afferents requires further investigation, particularly in light of recent evidence that renal denervation can successfully treat arterial hypertension (16) and affects glucose metabolism (38) .
In summary, N-type Ca 2ϩ channel (Cav2.2) currents in rat DRG neurons that receive sensory afferent input from the kidney are inhibited by NE via activation of ␣ 2 -adrenoreceptors. Given that sympathetic nerve fibers contact peptidergic afferent nerve fibers in the kidney as well as their cell soma within the DRG, this might be a mechanism by which NE regulates renal afferent peptidergic neuron excitability and/or neurotransmitter release from their fiber endings.
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